Use of the Decipher genomic classifier among men with prostate cancer in the United States

• Published in: JNCI cancer spectrum 2023-08, Vol.7 (5)
• Main Authors: Zaorsky, Nicholas G, Proudfoot, James A, Jia, Angela Y, Zuhour, Raed, Vince Jr, Randy, Liu, Yang, Zhao, Xin, Hu, Jim, Schussler, Nicola C, Stevens, Jennifer L, Bentler, Suzanne, Cress, Rosemary D, Doherty, Jennifer A, Durbin, Eric B, Gershman, Susan, Cheng, Iona, Gonsalves, Lou, Hernandez, Brenda Y, Liu, Lihua, Morawski, Bożena M, Schymura, Maria, Schwartz, Stephen M, Ward, Kevin C, Wiggins, Charles, Wu, Xiao-Cheng, Shoag, Jonathan E, Ponsky, Lee, Dal Pra, Alan, Schaeffer, Edward M, Ross, Ashley E, Sun, Yilun, Davicioni, Elai, Petkov, Valentina, Spratt, Daniel E
• Format: Article
• Language: English
• Subjects: Genomics; Humans; Male; Prostate - pathology; Prostate - surgery; Prostate-Specific Antigen; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - genetics; Prostatic Neoplasms - therapy; Risk Assessment - methods; United States - epidemiology
• ISSN: 2515-5091; 2515-5091
• DOI: 10.1093/jncics/pkad052

Abstract Background Management of localized or recurrent prostate cancer since the 1990s has been based on risk stratification using clinicopathological variables, including Gleason score, T stage (based on digital rectal exam), and prostate-specific antigen (PSA). In this study a novel prognostic test, the Decipher Prostate Genomic Classifier (GC), was used to stratify risk of prostate cancer progression in a US national database of men with prostate cancer. Methods Records of prostate cancer cases from participating SEER (Surveillance, Epidemiology, and End Results) program registries, diagnosed during the period from 2010 through 2018, were linked to records of testing with the GC prognostic test. Multivariable analysis was used to quantify the association between GC scores or risk groups and use of definitive local therapy after diagnosis in the GC biopsy-tested cohort and postoperative radiotherapy in the GC-tested cohort as well as adverse pathological findings after prostatectomy. Results A total of 572 545 patients were included in the analysis, of whom 8927 patients underwent GC testing. GC biopsy-tested patients were more likely to undergo active active surveillance or watchful waiting than untested patients (odds ratio [OR] =2.21, 95% confidence interval [CI] = 2.04 to 2.38, P